ÌÇÐÄ´«Ã½

Skip to main content
 
Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
ÌÇÐÄ´«Ã½

Incidence and outcomes of patients with atrial fibrillation and major bleeding complications: from the TREAT-AF study.

ÌÇÐÄ´«Ã½

Incidence and outcomes of patients with atrial fibrillation and major bleeding complications: from the TREAT-AF study. Journal of interventional cardiac electrophysiology : an international journal of arrhythmias and pacing Perino, A. C., Kaiser, D. W., Lee, R. J., Fan, J. n., Askari, M. n., Schmitt, S. K., Turakhia, M. P. 2020

Abstract

Optimal stroke prevention strategies for patients with atrial fibrillation (AF) who experience a major bleed are poorly defined. We sought to estimate the effectiveness and safety of oral anticoagulation (OAC) represcription after an OAC contraindication.TREAT-AF is a retrospective cohort study of patients with newly diagnosed AF (2004-2012), treated in the Veterans Health Administration. From this cohort, we identified patients with a contraindication to OAC after AF diagnoses, defined as incident intracranial bleeding, non-intracranial bleeding requiring hospitalization, or unrepaired cerebral aneurysm or aortic dissection. We used multivariate Cox proportional hazards to estimate the association of OAC prescription in the 90 days following OAC contraindication to ischemic stroke and rebleeding.Among 167,190 patients with newly diagnosed AF (70?±?11 years, 1.7% female, CHA2DS2-VASc 2.7?±?1.7), 19,285 patients (11.5%) had an incident bleed (n?=?18,342) or an unrepaired cerebral aneurysm or aortic dissection (n?=?943). For OAC-contraindicated patients with a CHA2DS2-VASc =2 (N?=?16,194), OAC was represcribed in 4075 patients (25%) and was associated with a higher risk of non-intracranial bleeding (HR 1.49; 95% CI 1.37-1.61; p?

View details for

View details for